Clinical Outcomes Following Letrozole Treatment according to Estrogen Receptor Expression in Postmenopausal Women: LETTER Study (KBCSG-006) / 한국유방암학회지
Sung-Gwe AHN; Seok-Jin NAM; Sei-Hyun AHN; Yongsik JUNG; Heung-Kyu PARK; Soo-Jung LEE; Sung-Soo KANG; Wonshik HAN; Kyong-Hwa PARK; Yong-Lai PARK; Jihyoun LEE; Hyun-Jo YOUN; Jun-Hyun KIM; Youngbum YOO; Jeong-Yoon SONG; Byung-Kyun KO; Geumhee GWAK; Min-Sung CHUNG; Sung-Yong KIM; Seo-Heon CHO; Doyil KIM; Myung-Chul CHANG; Byung-In MOON; Lee-Su KIM; Sei-Joong KIM; Min-Ho PARK; Tae-Hyun KIM; Jihyoung CHO; Cheol-Wan LIM; Young-Tae BAE; Gyungyub GONG; Young-Kyung BAE; Ahwon LEE; Joon JEONG.
Journal of Breast Cancer
; : 164-174, 2021.
Artículo
en Inglés
| WPRIM | ID: wpr-898981
Purpose@#In this trial, we investigated the efficacy and safety of adjuvant letrozole for hormone receptor (HR)-positive breast cancer. Here, we report the clinical outcome in postmenopausal women with HR-positive breast cancer treated with adjuvant letrozole according to estrogen receptor (ER) expression levels. @*Methods@#In this multi-institutional, open-label, observational study, postmenopausal patients with HR-positive breast cancer received adjuvant letrozole (2.5 mg/daily) for 5 years unless they experienced disease progression or unacceptable toxicity or withdrew their consent. The patients were stratified into the following 3 groups according to ER expression levels using a modified Allred score (AS) low, intermediate, and high (AS 3–4, 5–6, and 7–8, respectively). ER expression was centrally reviewed. The primary objective was the 5-year disease-free survival (DFS) rate. @*Results@#Between April 25, 2010, and February 5, 2014, 440 patients were enrolled. With a median follow-up of 62.0 months, the 5-year DFS rate in all patients was 94.2% (95% confidence interval [CI], 91.8–96.6). The 5-year DFS and recurrence-free survival (RFS) rates did not differ according to ER expression; the 5-year DFS rates were 94.3% and 94.1%in the low-to-intermediate and high expression groups, respectively (p = 0.6), and the corresponding 5-year RFS rates were 95.7% and 95.4%, respectively (p = 0.7). Furthermore, 25 patients discontinued letrozole because of drug toxicity. @*Conclusion@#Treatment with adjuvant letrozole showed very favorable treatment outcomes and good tolerability among Korean postmenopausal women with ER-positive breast cancer, independent of ER expression.
Biblioteca responsable:
WPRO
Texto completo
Documentos relacionados